• Explore /
  • Poster
  • / Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.

Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.

Abstract Video & Slides Poster

Authors

Wojciech Jurczak

Wojciech Jurczak

Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

Wojciech Jurczak , Andrzej Pluta , Malgorzata Wach , Daniel Lysak , Martin Simkovic , Iryna Kriachok , Árpád Illés , Javier De La Serna , Sean Dolan , Philip Campbell , Gerardo Musuraca , Abraham Jacob , Eric Joseph Avery , Jae Hoon Lee , Ganna Usenko , Min Hui Wang , Ting Yu , Paolo Ghia

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT02970318

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7538)

DOI

10.1200/JCO.2022.40.16_suppl.7538

Abstract #

7538

Poster Bd #

191

Abstract Disclosures

Similar Posters

First Author: Jennifer R. Brown

First Author: Jeffrey Alan Jones

First Author: Alexander Xenakis

First Author: Gilles A. Salles